We are contrasting Alterity Therapeutics Limited (NASDAQ:ATHE) and Aevi Genomic Medicine Inc. (NASDAQ:GNMX) on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alterity Therapeutics Limited | 1 | 0.00 | N/A | -0.78 | 0.00 |
| Aevi Genomic Medicine Inc. | N/A | 0.00 | N/A | -0.43 | 0.00 |
Table 1 shows the gross revenue, earnings per share and valuation for Alterity Therapeutics Limited and Aevi Genomic Medicine Inc.
Profitability
Table 2 represents Alterity Therapeutics Limited (NASDAQ:ATHE) and Aevi Genomic Medicine Inc. (NASDAQ:GNMX)’s return on assets, net margins and return on equity.
| Net Margins | Return on Equity | Return on Assets | |
| Alterity Therapeutics Limited | 0.00% | -56.4% | -49.9% |
| Aevi Genomic Medicine Inc. | 0.00% | -264.5% | -178.4% |
Risk & Volatility
Alterity Therapeutics Limited is 3.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 1.03. Competitively, Aevi Genomic Medicine Inc.’s 24.00% volatility makes it less volatile than Standard and Poor’s 500, because of the 0.76 beta.
Liquidity
Alterity Therapeutics Limited has a Current Ratio of 4.4 and a Quick Ratio of 4.4. Competitively, Aevi Genomic Medicine Inc.’s Current Ratio is 1.9 and has 1.9 Quick Ratio. Alterity Therapeutics Limited’s better ability to pay short and long-term obligations than Aevi Genomic Medicine Inc.
Institutional and Insider Ownership
The shares of both Alterity Therapeutics Limited and Aevi Genomic Medicine Inc. are owned by institutional investors at 3.1% and 6.4% respectively. Insiders held 18.7% of Alterity Therapeutics Limited shares. Comparatively, 42.43% are Aevi Genomic Medicine Inc.’s share held by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Alterity Therapeutics Limited | -9.73% | -21.09% | -40.59% | -28.87% | -53.26% | -21.09% |
| Aevi Genomic Medicine Inc. | -9.48% | -7.97% | -32.82% | -17.4% | -83.14% | -76.4% |
For the past year Alterity Therapeutics Limited has stronger performance than Aevi Genomic Medicine Inc.
Summary
Alterity Therapeutics Limited beats Aevi Genomic Medicine Inc. on 5 of the 6 factors.
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
